Skip to main content

Fiscal Wizard · Single-issue tearsheet

NAGE / Jun 22, 2026 Run #7650

NAGE

Niagen Bioscience, Inc.

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Composite verdict

D 41.8 / 100
Bearish setup · Trend Following 11 drivers · 2 gates blocking
  • Relative Strength vs SPY
  • Keltner Channels
  • Trendline Break
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 104th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 3Mean-reversion Neutral 49

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -59%
Asset value $0.96Earnings power value $2.98Price $3.50

Priced above its no-growth earnings power value ($2.98/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Strong

83.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
Cash Conversion Cycle 8
Asset Turnover 100
Inventory Turnover 11

Technicals Bearish

0.0 / 100

Bearish setup leads (Relative Strength vs SPY, 52-Week Proximity, Keltner Channels); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Relative Strength vs SPY 11
Trendline Break 22
Keltner Channels 22

Risk Gates

2 blocking 6 caution

2 guards active, 19 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for NAGE.